Johnson & Johnson Files Q1 2024 10-Q
Ticker: JNJ · Form: 10-Q · Filed: 2024-05-01T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, quarterly-report, financials
Related Tickers: JNJ
TL;DR
JNJ 10-Q filed for Q1 2024. Financials are in.
AI Summary
Johnson & Johnson filed its 10-Q for the period ending March 31, 2024. The company reported its financial results for the first quarter of 2024. Key financial data and operational details are disclosed in this filing, which is a standard requirement for publicly traded companies.
Why It Matters
This filing provides investors and analysts with a detailed look at Johnson & Johnson's financial performance and position as of the end of the first quarter of 2024.
Risk Assessment
Risk Level: low — This is a routine quarterly filing providing financial updates, not indicating new or elevated risks.
Key Players & Entities
- JOHNSON & JOHNSON (company) — Filer
- 20240331 (date) — Period of Report
- 20240501 (date) — Filed as of Date
- 08933 (dollar_amount) — ZIP Code
FAQ
What is the reporting period for this 10-Q filing?
The Conformed Period of Report is 20240331, indicating the filing covers the period ending March 31, 2024.
When was this 10-Q filed with the SEC?
This 10-Q was filed on 20240501.
What is Johnson & Johnson's Standard Industrial Classification code?
Johnson & Johnson's Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
What is the company's primary business address?
The business address is One Johnson & Johnson Plaza, New Brunswick, NJ, 08933.
What is the fiscal year end for Johnson & Johnson?
Johnson & Johnson's fiscal year ends on 1229.
From the Filing
0000200406-24-000049.txt : 20240501 0000200406-24-000049.hdr.sgml : 20240501 20240501070936 ACCESSION NUMBER: 0000200406-24-000049 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 93 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240501 DATE AS OF CHANGE: 20240501 FILER: COMPANY DATA: COMPANY CONFORMED NAME: JOHNSON & JOHNSON CENTRAL INDEX KEY: 0000200406 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 221024240 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1229 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-03215 FILM NUMBER: 24900037 BUSINESS ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 BUSINESS PHONE: 732-524-2455 MAIL ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 10-Q 1 jnj-20240331.htm 10-Q jnj-20240331 0000200406 12/29 2024 Q1 FALSE 0000200406 2024-01-01 2024-03-31 0000200406 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000200406 jnj:A0.650NotesDue2024Member 2024-01-01 2024-03-31 0000200406 jnj:A5.50NotesDue2024Member 2024-01-01 2024-03-31 0000200406 jnj:A1.150NotesDue2028Member 2024-01-01 2024-03-31 0000200406 jnj:A1.650NotesDue2035Member 2024-01-01 2024-03-31 0000200406 2024-04-25 xbrli:shares 0000200406 2024-03-31 iso4217:USD 0000200406 2023-12-31 iso4217:USD xbrli:shares xbrli:pure 0000200406 2023-01-02 2023-04-02 0000200406 us-gaap:RetainedEarningsMember 2023-12-31 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000200406 us-gaap:CommonStockMember 2023-12-31 0000200406 us-gaap:TreasuryStockCommonMember 2023-12-31 0000200406 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000200406 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0000200406 us-gaap:RetainedEarningsMember 2024-03-31 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000200406 us-gaap:CommonStockMember 2024-03-31 0000200406 us-gaap:TreasuryStockCommonMember 2024-03-31 0000200406 2023-01-01 0000200406 us-gaap:RetainedEarningsMember 2023-01-01 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 0000200406 us-gaap:CommonStockMember 2023-01-01 0000200406 us-gaap:TreasuryStockCommonMember 2023-01-01 0000200406 us-gaap:RetainedEarningsMember 2023-01-02 2023-04-02 0000200406 us-gaap:TreasuryStockCommonMember 2023-01-02 2023-04-02 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-02 2023-04-02 0000200406 2023-04-02 0000200406 us-gaap:RetainedEarningsMember 2023-04-02 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-02 0000200406 us-gaap:CommonStockMember 2023-04-02 0000200406 us-gaap:TreasuryStockCommonMember 2023-04-02 0000200406 jnj:PatentsAndTrademarksMember 2024-03-31 0000200406 jnj:PatentsAndTrademarksMember 2023-12-31 0000200406 us-gaap:OtherIntangibleAssetsMember 2024-03-31 0000200406 us-gaap:OtherIntangibleAssetsMember 2023-12-31 0000200406 us-gaap:TrademarksMember 2024-03-31 0000200406 us-gaap:TrademarksMember 2023-12-31 0000200406 jnj:PurchasedInProcessResearchAndDevelopmentMember 2024-03-31 0000200406 jnj:PurchasedInProcessResearchAndDevelopmentMember 2023-12-31 0000200406 jnj:InnovativeMedicineMember 2023-12-31 0000200406 jnj:MedTechMember 2023-12-31 0000200406 jnj:InnovativeMedicineMember 2024-01-01 2024-03-31 0000200406 jnj:MedTechMember 2024-01-01 2024-03-31 0000200406 jnj:InnovativeMedicineMember 2024-03-31 0000200406 jnj:MedTechMember 2024-03-31 0000200406 us-gaap:ForeignExchangeContractMember 2024-03-31 0000200406 us-gaap:CrossCurrencyInterestRateContractMember 2024-03-31 0000200406 us-gaap:InterestRateSwapMember 2024-03-31 0000200406 us-gaap:ForeignExchangeContractMember 2023-12-31 0000200406 us-gaap:CrossCurrencyInterestRateContractMember 2023-12-31 0000200406 us-gaap:InterestRateSwapMember 2023-12-31 0000200406 us-gaap:InterestRateSwapMember us-gaap:Fa